Gever, JR; Soto, R; Henningsen, RA; Martin, RS; Hackos, DH; Panicker, S; ... Ford, APDW; + view all Gever, JR; Soto, R; Henningsen, RA; Martin, RS; Hackos, DH; Panicker, S; Rubas, W; Oglesby, IB; Dillon, MP; Milla, ME; Burnstock, G; Ford, APDW; - view fewer (2010) AF-353, a novel, potent and orally bioavailable P2X3/P2X2/3 receptor antagonist. BRIT J PHARMACOL , 160 (6) 1387 - 1398. 10.1111/j.1476-5381.2010.00796.x.
Full text not available from this repository.
Background and purpose:Purinoceptors containing the P2X3 subunit (P2X3 homotrimeric and P2X2/3 heterotrimeric) are members of the P2X family of ion channels gated by ATP and may participate in primary afferent sensitization in a variety of pain-related diseases. The current work describes the in vitro pharmacological characteristics of AF-353, a novel, orally bioavailable, highly potent and selective P2X3/P2X2/3 receptor antagonist.Experimental approach:The antagonistic potencies (pIC(50)) of AF-353 for rat and human P2X3 and human P2X2/3 receptors were determined using methods of radioligand binding, intracellular calcium flux and whole cell voltage-clamp electrophysiology.Key results:The pIC(50) estimates for these receptors ranged from 7.3 to 8.5, while concentrations 300-fold higher had little or no effect on other P2X channels or on an assortment of receptors, enzymes and transporter proteins. In contrast to A-317491 and TNP-ATP, competition binding and intracellular calcium flux experiments suggested that AF-353 inhibits activation by ATP in a non-competitive fashion. Favourable pharmacokinetic parameters were observed in rat, with good oral bioavailability (%F = 32.9), reasonable half-life (t(1/2) = 1.63 h) and plasma-free fraction (98.2% protein bound).Conclusions and implications:The combination of a favourable pharmacokinetic profile with the antagonist potency and selectivity for P2X3 and P2X2/3 receptors suggests that AF-353 is an excellent in vivo tool compound for study of these channels in animal models and demonstrates the feasibility of identifying and optimizing molecules into potential clinical candidates, and, ultimately, into a novel class of therapeutics for the treatment of pain-related disorders.
|Title:||AF-353, a novel, potent and orally bioavailable P2X3/P2X2/3 receptor antagonist|
|Keywords:||P2X, purinergic, ATP, ion channel, antagonist, urinary bladder, CHRONIC CONSTRICTION INJURY, NEUROPATHIC PAIN, P2X(3) RECEPTOR, SENSORY NEURONS, P2X(2/3) RECEPTORS, TNP-ATP, SMALL-INTESTINE, RAT, A-317491, MICE|
|UCL classification:||UCL > School of Life and Medical Sciences > Faculty of Life Sciences > Biosciences (Division of)|
Archive Staff Only: edit this record